MacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) VP Jeffrey Stuart Peters sold 31,105 shares of the business's stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $4.15, for a total transaction of $129,085.75. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
MacroGenics Stock Performance
Shares of NASDAQ:MGNX opened at $4.07 on Friday. The company has a market cap of $259.26 million, a PE ratio of -18.50 and a beta of 1.20. MacroGenics, Inc. has a 52 week low of $1.29 and a 52 week high of $5.08. The firm has a 50 day simple moving average of $4.24 and a 200 day simple moving average of $3.46.
MacroGenics (NASDAQ:MGNX - Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported $0.31 EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.39. MacroGenics had a negative net margin of 8.70% and a negative return on equity of 109.26%. The firm had revenue of $32.83 million during the quarter, compared to analyst estimates of $59.14 million. On average, equities analysts predict that MacroGenics, Inc. will post -1.48 earnings per share for the current year.
Analyst Upgrades and Downgrades
Several analysts have recently commented on MGNX shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of MacroGenics in a research report on Wednesday, August 5th. B. Riley Financial upped their price target on MacroGenics from $9.00 to $11.00 and gave the company a "buy" rating in a research report on Monday. Two analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $6.33.
Read Our Latest Stock Report on MGNX
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Legal & General Group Plc acquired a new stake in MacroGenics during the second quarter valued at $28,000. Walleye Capital LLC grew its stake in MacroGenics by 31.8% in the fourth quarter. Walleye Capital LLC now owns 33,180 shares of the biopharmaceutical company's stock valued at $53,000 after purchasing an additional 8,000 shares in the last quarter. Cresset Asset Management LLC increased its position in MacroGenics by 52.3% in the 2nd quarter. Cresset Asset Management LLC now owns 26,720 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 9,172 shares during the last quarter. State of Wyoming increased its position in MacroGenics by 41.8% in the 2nd quarter. State of Wyoming now owns 31,557 shares of the biopharmaceutical company's stock worth $38,000 after purchasing an additional 9,295 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of MacroGenics by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 4,224,234 shares of the biopharmaceutical company's stock worth $7,097,000 after purchasing an additional 11,120 shares in the last quarter. 96.89% of the stock is owned by hedge funds and other institutional investors.
About MacroGenics
(
Get Free Report)
MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody–based therapeutics for the treatment of cancer and autoimmune diseases. The company leverages proprietary Fc engineering technologies to enhance immune engagement and extend the activity of its antibodies. Since its founding in 2000, MacroGenics has advanced several product candidates through clinical trials, most notably margetuximab, a HER2-targeted antibody designed to improve outcomes in patients with HER2-positive breast cancer.
Central to MacroGenics' research platform are its ADAPTIR and Trident bispecific antibody technologies.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
